IFNL3 and Hepatic fibrosis: In the evaluation of predictors of response to TT among previous treated G1 CHC patients other significant factor needing to be evaluated are the severity of liver fibrosis, and, even if at a les extent, the sub-type of viral genotype, but not IL28B genotype.